Vaccine GMP Reevaluation Needed, NVAC Draft Report On Shortages Says
Executive Summary
Good manufacturing practices for vaccines should be reevaluated in light of recent vaccine shortages, according to a National Vaccine Advisory Committee draft report
You may also be interested in...
Flu Vaccine Schedule Expansion Could Cost Public Sector $60 Mil. Annually
Expanding influenza vaccination recommendations to include infants between six and 23 months and children who are household contacts of high-risk groups could increase costs to the public sector by $59.6 mil. annually
Flu Vaccine Schedule Expansion Could Cost Public Sector $60 Mil. Annually
Expanding influenza vaccination recommendations to include infants between six and 23 months and children who are household contacts of high-risk groups could increase costs to the public sector by $59.6 mil. annually
FDA Evaluating Vaccine GMP Requirements To Assess Impact on Supply
FDA is re-evaluating its approach to good manufacturing practices, FDA Acting Commissioner Lester Crawford, PhD, suggested during a June 12 hearing on vaccine supply